Posted 4/5/2024
The first conference held under the auspices of Frederick National Laboratory’s (FNL’s) Scientific Standards Hub , an...
Posted 1/25/2024
Technologies invented and patented by researchers at the Frederick National Laboratory for Cancer Research are on...
Posted 1/9/2024
Research led by the Frederick National Laboratory for Cancer Research (FNL) and Gilead Sciences shows the potential for...
All News
Real-world studies indicate NSAIDs improve lung cancer survival
Ethan Dmitrovsky, M.D.Posted 11/8/2022Common drugs for controlling pain and inflammation – such as aspirin and ibuprofen – improved overall lung cancer survival by a statistically significant margin in a long-term study of patient medical records. This finding called for more definitive randomized clinical trials.
Use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a survival rate of 29.7…
Renowned FNL scientist joins late father-in-law and world leaders as member of American Academy of Arts and Sciences
Basic Science Program, Mary Carrington, Ph.D.Posted 11/2/2022
Upon hearing earlier this year that she was elected to the prestigious American Academy of Arts and Sciences, cancer scientist Mary Carrington wished she could share the news with her beloved late father-in-law, a former law school dean at Duke.
She had only discovered Paul Carrington’s academy membership after he died last year, when she and her husband found the…
Annual Technology Showcase to spotlight collaboration opportunities with NCI and FNL
Partnership Development OfficePosted 8/18/2022
The National Cancer Institute and Frederick National Laboratory for Cancer Research will hold the annual Technology Showcase on Wednesday, Sept. 7 in a hybrid format to welcome in-person attendees as well as remote participants from around the United States and the world. The event is scheduled from noon to 5:30 pm ET at the FNL’s Advanced Technology Research Facility in…
BIO International Convention 2022: Pursuing the mission of the Frederick National Laboratory in San Diego
Partnership Development OfficePosted 8/4/2022Pursuing future partners and better weather, the Frederick National Laboratory for Cancer Research (FNL) recently attended the BIO 2022 International Convention in San Diego. This convention is one of the largest biotech partnering events internationally, with over 3,000 foreign and domestic companies represented at this year’s week-long June event. This setting created an…
Five new innovative projects awarded LDER funding
Laboratory-Directed Exploratory Research, Cancer Data Science Initiatives, AIDS and Cancer Virus Program, Basic Science ProgramPosted 7/21/2022Five new projects led by Frederick National Laboratory for Cancer Research (FNL) scientists have earned Laboratory Directed Exploratory Research (LDER) funding for the upcoming fiscal year.
The LDER program, which was modeled after the U.S. Department of Energy’s Laboratory Directed Research and Development program, provides FNL scientists the opportunity to compete for…
Hood College symposium to explore artificial intelligence in cancer research and clinical care
Partnership Development Office, Cancer Data Science InitiativesPosted 7/7/2022Some of the world’s top scientific leaders in the field will highlight the current progress of artificial intelligence (AI) applications in cancer research and clinical care at a scientific symposium hosted by Hood College in partnership with the Frederick National Laboratory for Cancer Research, September 2022.
Cancer researchers are invited to attend the conference…
COVID-19 vaccines bring nanomedicine back into the spotlight
Nanotechnology Characterization LaboratoryPosted 6/15/2022The success of today’s COVID-19 vaccines has given medical nanotechnology a long-awaited boost, with a renewed interest in its potential for treating disease among big pharma and small start-ups.
Over the years, nanotechnology has had its ups and downs in the public eye, cycling from peaks of excitement and fanfare–and a little too much hype–to falling out of favor because…
Nanotechnology experts share insights as they see similarities in hypersensitivity reactions to nanomedicine and mRNA vaccines
Nanotechnology Characterization LaboratoryPosted 5/18/2022When nanoparticle-based mRNA COVID-19 vaccines were made available in December 2020 and the media began to report the incidence of rare but troubling anaphylaxis, nanomedicine experts including Frederick National Laboratory’s Marina Dobrovolskaia recognized those hypersensitivity reactions.
“Everything they reported symptomatically sounded so familiar to us from our work…
Computing collaboration makes massive microscopy analyses possible
Posted 5/11/2022On any given day, microscopist Susan Lea, D.Phil., and her team at NCI at Frederick collect more data than can fit on any standard hard drive, creating a challenge for data storage and analysis.
Their average data collection is 5 terabytes, a quantity roughly 20 times the storage capacity of a 256-gigabyte laptop or the equivalent of storing about 1,250 movies.
The…
Nanoparticle-based flu vaccine performs well in early phase clinical trial
Vaccine Clinical Materials ProgramPosted 5/5/2022A nanoparticle-based flu vaccine discovered and developed by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), was manufactured by Frederick National Laboratory (FNL) for a Vaccine Research Center Phase 1 clinical trial. The vaccine was found to be safe, well-tolerated, and immunogenic against multiple flu subtypes and, with further…
Media Inquiries
For all media related questions please contact:
Mary Ellen Hackett
Manager, Communications Office